WO2008090717A1 - Adam阻害剤 - Google Patents

Adam阻害剤 Download PDF

Info

Publication number
WO2008090717A1
WO2008090717A1 PCT/JP2007/075121 JP2007075121W WO2008090717A1 WO 2008090717 A1 WO2008090717 A1 WO 2008090717A1 JP 2007075121 W JP2007075121 W JP 2007075121W WO 2008090717 A1 WO2008090717 A1 WO 2008090717A1
Authority
WO
WIPO (PCT)
Prior art keywords
adam
formula
adam inhibitor
inhibitor
disclosed
Prior art date
Application number
PCT/JP2007/075121
Other languages
English (en)
French (fr)
Inventor
Takuya Hiruma
Hirotada Fukunishi
Masaru Suetsugu
Yukiko Matsunaga
Satoshi Amano
Michio Shibata
Original Assignee
Shiseido Company, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Company, Ltd. filed Critical Shiseido Company, Ltd.
Priority to US12/524,543 priority Critical patent/US20100113590A1/en
Priority to EP07860343A priority patent/EP2123272A4/en
Priority to KR1020097010609A priority patent/KR20090112629A/ko
Publication of WO2008090717A1 publication Critical patent/WO2008090717A1/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62Three oxygen atoms, e.g. ascorbic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74Biological properties of particular ingredients
    • A61K2800/78Enzyme modulators, e.g. Enzyme agonists
    • A61K2800/782Enzyme inhibitors; Enzyme antagonists

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ADAMの活性上昇に起因する病態を防止または改善することができるADAM阻害剤を提供する。 下記一般式(1)で表されるアスコルビン酸誘導体またはその塩からなるものとする。 【化1】 (式中、Rは、炭素数1~22の直鎖または分岐のアルキル基を表す。)
PCT/JP2007/075121 2007-01-26 2007-12-27 Adam阻害剤 WO2008090717A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/524,543 US20100113590A1 (en) 2007-01-26 2007-12-27 Adam inhibitor
EP07860343A EP2123272A4 (en) 2007-01-26 2007-12-27 ADAM INHIBITORS
KR1020097010609A KR20090112629A (ko) 2007-01-26 2007-12-27 Adam 저해제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-016536 2007-01-26
JP2007016536A JP2008184387A (ja) 2007-01-26 2007-01-26 Adam阻害剤

Publications (1)

Publication Number Publication Date
WO2008090717A1 true WO2008090717A1 (ja) 2008-07-31

Family

ID=39644292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/075121 WO2008090717A1 (ja) 2007-01-26 2007-12-27 Adam阻害剤

Country Status (7)

Country Link
US (1) US20100113590A1 (ja)
EP (1) EP2123272A4 (ja)
JP (1) JP2008184387A (ja)
KR (1) KR20090112629A (ja)
CN (1) CN101594860A (ja)
TW (1) TW200835506A (ja)
WO (1) WO2008090717A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091138A1 (ja) * 2010-12-28 2012-07-05 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法
JPWO2015190505A1 (ja) * 2014-06-10 2017-04-20 味の素株式会社 3−o−アルキル−l−アスコルビン酸又はその塩を含有する化粧料組成物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2955493B1 (fr) * 2010-01-28 2012-02-24 Oreal Utilisation de derives d'acide ascorbique en coloration des fibres keratiniques humaines, composition les comprenant, procede de coloration et dispositif
JP5888667B2 (ja) * 2010-04-30 2016-03-22 国立大学法人名古屋大学 Adam作用阻害物質のスクリーニング方法、仮足の保持方法、仮足保持剤、仮足の制御物質のスクリーニング方法、及びadam作用阻害剤
DE102013208865A1 (de) * 2013-05-14 2014-11-20 Beiersdorf Ag Stabilisierte Zubereitungen mit einem Gehalt an Ascorbinsäure und Phosphationen
JP7417291B2 (ja) 2019-03-04 2024-01-18 丸善製薬株式会社 外用剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221611A (ja) * 1986-03-20 1987-09-29 Kanebo Ltd 皮膚化粧料
JPS62226910A (ja) * 1986-03-26 1987-10-05 Kanebo Ltd 皮膚化粧料
JPH02235813A (ja) * 1989-03-09 1990-09-18 Jiro Fujimoto 抗腫瘍剤
JPH04128225A (ja) * 1989-09-12 1992-04-28 Kokuritsu Gan Center Souchiyou 抗腫瘍剤
JPH0558892A (ja) * 1991-09-06 1993-03-09 Jiro Fujimoto 発癌防止剤
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH045214A (ja) * 1990-04-21 1992-01-09 Atsushi Nonaka アスコルビン酸誘導体を含む化粧品及び外用薬
TW325997B (en) * 1993-02-02 1998-02-01 Senju Pharma Co Pharmaceutical composition for preventing and treating retinal diseases

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62221611A (ja) * 1986-03-20 1987-09-29 Kanebo Ltd 皮膚化粧料
JPS62226910A (ja) * 1986-03-26 1987-10-05 Kanebo Ltd 皮膚化粧料
JPH02235813A (ja) * 1989-03-09 1990-09-18 Jiro Fujimoto 抗腫瘍剤
JPH04128225A (ja) * 1989-09-12 1992-04-28 Kokuritsu Gan Center Souchiyou 抗腫瘍剤
JPH0558892A (ja) * 1991-09-06 1993-03-09 Jiro Fujimoto 発癌防止剤
WO1996030012A1 (en) * 1995-03-24 1996-10-03 Defeudis Francis V Methods for treating conditions associated with excess nitric oxide

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ARRIBAS J; BECH-SERRA JJ; SANTIAGO-JOSEFAT B: "ADAMs, cell migration and cancer", CANCER METASTASIS REV, vol. 25, 2006, pages 57 - 68, XP019392612, DOI: doi:10.1007/s10555-006-7889-6
ASAKURA, M. ET AL.: "Cardiac hypertrophy is inhibited by antagonism ofADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy", NAT. MED., vol. 8, 2002, pages 35 - 40, XP002965243, DOI: doi:10.1038/nm0102-35
DEFEUDIS F.V.: "Excess EDRF/NO, a potentially deleterious condition that may be involved in accelerated atherogenesis and other chronic disease states", GENERAL PHARMACOLOGY, vol. 26, no. 4, 1995, pages 667 - 680, XP000576601 *
HINO T. ET AL.: "Hydrogen peroxide enhances shedding of type I soluble tumor necrosis factor receptor from pulmonary epithelial cells", AM. J. RESPIR. CELL MOL. BIOL., vol. 20, no. 1, 1999, pages 122 - 128, XP008112080 *
KODAMA T ET AL.: "ADAM12 is selectively overexpressed in human glioblastomas", GLIOBLASTOMA CELL PROLIFERATION AND SHEDDING OF HEPARIN-BINDING EPIDERMAL, vol. 165, 2004, pages 1743 - 53
KUBO H. ET AL.: "Zenritsusen Gan Ni Okeru ADAM0 to Sanka Stress tono Kanren", THE JAPANESE JOURNAL OF UROLOGY, vol. 96, no. 2, 2005, pages 215, XP008112117 *
LIU PC; LIU X; LI Y ET AL.: "Identification of ADAM10 as a Major Source of HER2 Ectodomain Sheddase Activity in HER2 Overexpressing Breast Cancer Cells", CANCER BIOL THER, vol. 5, 2006, pages 657 - 64, XP008157971, DOI: doi:10.4161/cbt.5.6.2708
PIETRI M. ET AL.: "Reactive oxygen species-dependent TNF-alpha converting enzyme activation through stimulation of 5-HT2B and alpha1D autoreceptors in neuronal cells", FASEB J., vol. 19, no. 9, 2005, pages 1078 - 1087, XP008112027 *
ROCKS N; PAULISSEN G; QUESADA CALVO F ET AL.: "Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)", BR J CANCER, vol. 94, 2006, pages 724 - 30, XP002617703, DOI: doi:10.1038/SJ.BJC.6602990
SANDERSON M.P. ET AL.: "Hydrogen peroxide and endothelin-1 are novel activators of betacellulin ectodomain shedding", J. CELL BIOCHEM., vol. 99, no. 2, 2006, pages 609 - 623, XP008112029 *
See also references of EP2123272A4 *
SUNG S. ET AL.: "Oxidative Stress Induces ADAM9 Protein Expression in Human Prostate Cancer Cells", CANCER RESEARCH, vol. 66, no. 19, 2006, pages 9519 - 9526, XP008112026 *
TERAO S. ET AL.: "2-0-Octadecyl Ascorbic Acid (CV-3611): Gosei to Kassei Sanso-shu Shokyo Sayo", VITAMINS, vol. 62, no. 11, 1988, pages 631, XP008113784 *
YANG P. ET AL.: "The ADAMs family: coordinators of nervous system development, plasticity and repair", PROG. NEUROBIOL., vol. 79, no. 2, 2006, pages 73 - 94, XP025050607 *
YANG P; BAKER KA; HAGG T: "The ADAMs family: Coordinators of nervous system development, plasticity and repair", PROG NEUROBIOL, vol. 79, 2006, pages 73 - 94, XP025050607, DOI: doi:10.1016/j.pneurobio.2006.05.001
ZHANG Z. ET AL.: "Reactive oxygen species mediate tumor necrosis factor alpha-converting, enzyme-dependent ectodomain shedding inuduced by phorbol myristate acetate", FASEB J., vol. 15, no. 2, 2001, pages 303 - 305, XP008112028 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012091138A1 (ja) * 2010-12-28 2012-07-05 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法
KR20140004701A (ko) * 2010-12-28 2014-01-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 알츠하이머 병의 진단약 및 진단 방법
JP5894085B2 (ja) * 2010-12-28 2016-03-23 大日本住友製薬株式会社 アルツハイマー病の診断薬及び診断方法
KR101883515B1 (ko) 2010-12-28 2018-07-30 다이닛본 스미토모 세이야꾸 가부시끼가이샤 알츠하이머 병의 진단약 및 진단 방법
US10393757B2 (en) 2010-12-28 2019-08-27 Dainippon Sumitomo Pharma Co., Ltd. Diagnostic drug and diagnostic method for Alzheimer's disease
JPWO2015190505A1 (ja) * 2014-06-10 2017-04-20 味の素株式会社 3−o−アルキル−l−アスコルビン酸又はその塩を含有する化粧料組成物

Also Published As

Publication number Publication date
JP2008184387A (ja) 2008-08-14
EP2123272A4 (en) 2010-04-21
KR20090112629A (ko) 2009-10-28
US20100113590A1 (en) 2010-05-06
TW200835506A (en) 2008-09-01
EP2123272A1 (en) 2009-11-25
CN101594860A (zh) 2009-12-02

Similar Documents

Publication Publication Date Title
HK1139381A1 (en) Bicyclic -amino acid derivative
MY150989A (en) Benzothiazole compounds useful for raf inhibition
ATE302001T1 (de) Stabilisierte askorbinsäurederivate
MX2010001240A (es) Derivado de oxopirazina y herbicida.
MY168201A (en) Agricultural And Horticultural Fungicidal Composition
WO2009041095A1 (ja) 染毛用染料及び染毛用組成物
WO2008126933A3 (en) Process for producing pesticidal benzamide compounds
IN2014CN03976A (ja)
WO2008090717A1 (ja) Adam阻害剤
AU2008255733A8 (en) Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
MY149180A (en) Uracil compound having inhibitor activity on human deoxyuridine triphosphatase or salt thereof
EP2412700A4 (en) PROCESS FOR PREPARING A BICYCLIC GAMMA AMINO ACID DERIVATIVE
MX2011009423A (es) Compuesto de piperazina capaz de inhibir prostaglandina d sintasa.
WO2009047298A3 (en) Dimers of harmol or of its derivatives and uses thereof
ATE500212T1 (de) Bisphenol monoester
WO2008090716A1 (ja) 抗しわ剤およびadam阻害剤
IL203744A (en) Amino phenyl acid compound, preparations containing it and its use
WO2009083532A3 (en) Novel method for the preparation of derivatives of dihydrotetraazapentacenes, products such as obtained, and uses thereof
EA201071424A1 (ru) Сульфонатные соли 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
WO2008136378A1 (ja) 新規なスルホンアミド誘導体またはその塩
EP2578617A4 (en) NYLON CONNECTION
UA111950C2 (uk) Гетероциклічні сполуки для лікування або профілактики розладів, викликаних зниженою нейротрансмісією серотоніну, норепінефрину або допаміну
GB2470170A (en) Dithienothiophene derivatives
SG194727A1 (en) Method for modification of organic molecules

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780046434.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07860343

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097010609

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12524543

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007860343

Country of ref document: EP